Market Research Report
Genitourinary Drugs Market By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, Erectile Dysfunction, UTI, Urinary Incontinence & STD), Product (Urologicals, Hormonal Therapy Drugs, Gynecological, Anti-infectives) & Segment Forecasts, 2013 - 2024
|Published by||Grand View Research, Inc.||Product code||408947|
|Published||Content info||110 Pages
Delivery time: 2-3 business days
|Genitourinary Drugs Market By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, Erectile Dysfunction, UTI, Urinary Incontinence & STD), Product (Urologicals, Hormonal Therapy Drugs, Gynecological, Anti-infectives) & Segment Forecasts, 2013 - 2024|
|Published: November 15, 2016||Content info: 110 Pages||
The genitourinary drugs market is expected to reach USD 29.7 billion by 2024, according to a new study by Grand View Research, Inc. This sector is expected to be driven by high R&D investments undertaken by the key companies, which is expected to result in the large-scale development of new drug candidates. This is presumed to increase the influx of drugs at a rapid pace into the genitourinary drugs market hence providing efficient treatment alternatives for numerous genitourinary disorders.
In addition, growing incidence of drug recalls is fueling the high clinical urgency to develop relatively new and advanced drugs with targeted therapy mechanisms. These factors cumulatively are slated to present the vertical with considerable growth opportunities over the forecast period.
Furthermore, increasing global presence of the major market players is anticipated to raise the awareness levels pertaining to treatment alternatives for genitourinary diseases amongst the patients as well as the physicians. This is further expected to widen the genitourinary market growth potential during the forecast period. Growing generic drugs competition, rising presence of counterfeit drugs, and with several patent expirations in the horizon, the market growth is expected to slow down over the coming years.